1044664-73-4
1044664-73-4
Chemical Structure
LQZ-7
- CAS No.: 1044664-73-4
- Formula:C24H19N7O4
- Molecular Weight:469.45
InChIKey: ONXLPQBYPUBYEJ-BRJLIKDPSA-N
SMILES: OC(C1=CC=CC(C2=CC=C(O2)/C=N/NC3=NC4=NON=C4N=C3NC5=C(C(C)=CC=C5)C)=C1)=O
Biological Activity: LQZ-7 is a survivin inhibitor and molecular glue degrader (Kd=0.24 μM). LQZ-7 binds to the dimerization interface of survivin, disrupting homodimerization and dissociating dimeric survivin into monomers, thereby accelerating its proteasome-dependent degradation. LQZ-7 does not affect the structurally similar dimeric proteins 14-3-3σ and 14-3-3δ, and can induce apoptosis, exhibiting cytotoxicity against cancer cells[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LQZ-7 | LQZ-7 is a survivin inhibitor and molecular glue degrader (Kd=0.24 μM). LQZ-7 binds to the dimerization interface of survivin, disrupting homodimerization and dissociating dimeric survivin into monomers, thereby accelerating its proteasome-dependent degradation. LQZ-7 does not affect the structurally similar dimeric proteins 14-3-3σ and 14-3-3δ, and can induce apoptosis, exhibiting cytotoxicity against cancer cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Qi J, et al. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer research. 2016 Jan 15;76(2):453-62.
- [2]. Martínez-García D, et al. Therapeutic strategies involving survivin inhibition in cancer. Medicinal research reviews. 2019 May;39(3):887-909.
- [3]. Li F, et al. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?. Journal of experimental & clinical cancer research : CR. 2019 Aug 22;38(1):368.
